Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TRN018
MIFTS: 62

Transitional Cell Carcinoma

Categories: Cancer diseases, Nephrological diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Transitional Cell Carcinoma

About this section

MalaCards integrated aliases for Transitional Cell Carcinoma:

Name: Transitional Cell Carcinoma 12 77 54 15 17
Carcinoma, Transitional Cell 45 74
Transitional Cell Neoplasm 12 74
Transitional Cell Carcinoma of Bladder 74
Carcinoma Transitional Cell 56
Urothelial Cell Carcinoma 12
Transitional Cell Tumor 12
Transitional Carcinoma 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2671
MeSH 45 D002295
NCIt 51 C2930 C6783
SNOMED-CT 69 27090000
Sources

Summaries for Transitional Cell Carcinoma

About this section
Disease Ontology : 12 A carcinoma that derives from transitional epithelial cells.

MalaCards based summary : Transitional Cell Carcinoma, also known as carcinoma, transitional cell, is related to renal pelvis transitional cell carcinoma and bladder papillary transitional cell neoplasm. An important gene associated with Transitional Cell Carcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are ERK Signaling and TGF-Beta Pathway. The drugs Vinblastine and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include kidney, lymph node and ovary, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 77 Transitional cell carcinoma, also urothelial carcinoma, is a type of cancer that typically occurs in the... more...

Sources

Related Diseases for Transitional Cell Carcinoma

About this section

Diseases related to Transitional Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 425)
# Related Disease Score Top Affiliating Genes
1 renal pelvis transitional cell carcinoma 34.2 KRT7 UPK3A
2 bladder papillary transitional cell neoplasm 34.0 FGFR3 KRT20 TP53
3 papillary transitional carcinoma 33.9 KRT20 KRT7
4 small cell carcinoma of the bladder 33.1 KRT20 KRT7
5 bladder urothelial carcinoma 32.7 CDH1 ERBB2 FGFR3 HRAS KRT20 KRT7
6 urinary tract papillary transitional cell benign neoplasm 32.4 FGFR3 KRT20 TP53
7 glandular cystitis 32.2 KRT20 KRT7 UPK3A
8 prostate cancer 31.5 CDH1 EGFR ERBB2 ERBB3 HRAS KRT18
9 in situ carcinoma 30.9 CDH1 CDKN2A EGFR ERBB2 TP53
10 bladder cancer 30.9 BRINP1 CDH1 CDKN2A EGFR ERBB2 FGFR3
11 inverted papilloma 30.6 CDKN2A KRT20 KRT7 TP53
12 papilloma 30.5 CDKN2A FGFR3 KRT20 KRT7 PTEN TP53
13 mammary paget's disease 30.4 EGFR ERBB2 KRT20 KRT7
14 myeloma, multiple 30.4 CDKN2A FGFR3 HRAS TP53
15 bladder squamous cell carcinoma 30.4 CDKN2A TP53 UPK2
16 renal cell carcinoma, nonpapillary 30.4 CDH1 EGFR IFNA2 KRT20 KRT7
17 merkel cell carcinoma 30.3 KRT20 KRT7 TP53
18 cervix carcinoma 30.3 CDKN2A FGFR3 TP53
19 cystitis 30.3 KRT20 PTGS2 UPK1A UPK3A
20 ovarian cancer 1 30.3 CDH1 ERBB2 KRT7 TP53
21 appendix adenocarcinoma 30.2 KRT20 KRT7
22 clear cell renal cell carcinoma 30.2 CDH1 KRT7 PTEN TP53
23 adenocarcinoma 30.2 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
24 paget disease, extramammary 30.1 ERBB2 KRT20 KRT7
25 non-invasive bladder papillary urothelial neoplasm 30.1 FGFR3 TP53 UPK3A
26 horseshoe kidney 30.1 EGFR KRT20 KRT7
27 suppression of tumorigenicity 12 30.0 CDH1 HRAS PTEN TP53 UPK3A
28 vesicoureteral reflux 1 30.0 UPK1A UPK1B UPK3A
29 cystadenocarcinoma 30.0 ERBB2 HRAS KRT7 TP53
30 squamous cell carcinoma 30.0 CDH1 CDKN2A EGFR ERBB2 FGFR3 HRAS
31 linitis plastica 29.9 CDH1 KRT20 KRT7
32 papillary adenocarcinoma 29.9 CDH1 ERBB2 KRT7 TP53
33 small cell carcinoma 29.9 CDKN2A EGFR KRT20 KRT7 PTEN TP53
34 carcinosarcoma 29.9 ERBB2 HRAS KRT7 PTEN TP53
35 ovarian brenner tumor 29.8 KRT18 KRT20 KRT7 UPK3A
36 mucinous adenocarcinoma 29.8 CDKN2A EGFR KRT20 KRT7
37 renal cell carcinoma, papillary, 1 29.7 ERBB2 FGFR3 HRAS KRT7 PTEN TP53
38 endometrial cancer 29.6 CDH1 CDKN2A EGFR ERBB2 HRAS KRT7
39 ovarian cancer 29.6 CDH1 EGFR ERBB2 ERBB3 KRT7 PTEN
40 cervical adenocarcinoma 29.5 CDKN2A ERBB2 KRT20 KRT7 PTGS2 TP53
41 adenoid cystic carcinoma 29.4 CDH1 ERBB2 HRAS KRT20 KRT7 PTEN
42 bladder disease 29.1 CDH1 CDKN2A ERBB2 FGFR3 KRT20 TP53
43 hepatocellular carcinoma 28.7 CDH1 CDKN2A EGFR HRAS KRT7 PTEN
44 cholangiocarcinoma 28.6 CDH1 CDKN2A EGFR ERBB2 KRT18 KRT20
45 lung cancer 28.5 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
46 colorectal cancer 28.4 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
47 sarcomatoid transitional cell carcinoma 12.6
48 ureter transitional cell carcinoma 12.5
49 ovary transitional cell carcinoma 12.5
50 infiltrating renal pelvis transitional cell carcinoma 12.4

Graphical network of the top 20 diseases related to Transitional Cell Carcinoma:



Diseases related to Transitional Cell Carcinoma
Sources

Symptoms & Phenotypes for Transitional Cell Carcinoma

About this section

GenomeRNAi Phenotypes related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.96 EGFR HRAS
2 Decreased viability GR00221-A-1 9.96 CDH1 CDKN2A EGFR FGFR3 HRAS
3 Decreased viability GR00221-A-2 9.96 FGFR3 HRAS
4 Decreased viability GR00221-A-3 9.96 CDKN2A FGFR3 HRAS
5 Decreased viability GR00221-A-4 9.96 CDKN2A EGFR
6 Decreased viability GR00301-A 9.96 CDH1
7 Decreased viability GR00402-S-2 9.96 CDH1 CDKN2A EGFR FGFR3 HRAS
8 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.55 EGFR ERBB2 FGFR3 HRAS PTEN
9 Reduced mammosphere formation GR00396-S 9.28 BRINP1 CDH1 EGFR ERBB3 HRAS KRT18

MGI Mouse Phenotypes related to Transitional Cell Carcinoma:

47 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 BRINP1 CDH1 CDKN2A EGFR ERBB2 ERBB3
2 growth/size/body region MP:0005378 10.34 BRINP1 CDH1 CDKN2A EGFR ERBB2 ERBB3
3 cellular MP:0005384 10.29 BRINP1 CDH1 CDKN2A EGFR ERBB2 ERBB3
4 mortality/aging MP:0010768 10.28 BRINP1 CDH1 CDKN2A EGFR ERBB2 ERBB3
5 digestive/alimentary MP:0005381 10.24 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
6 embryo MP:0005380 10.22 CDH1 CDKN2A EGFR ERBB2 ERBB3 KRT18
7 endocrine/exocrine gland MP:0005379 10.16 CDH1 CDKN2A EGFR ERBB2 ERBB3 HRAS
8 integument MP:0010771 10.16 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
9 neoplasm MP:0002006 10.1 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
10 normal MP:0002873 10.02 CDH1 EGFR ERBB2 ERBB3 FGFR3 HRAS
11 no phenotypic analysis MP:0003012 9.97 BRINP1 CDH1 CDKN2A EGFR FGFR3 HRAS
12 renal/urinary system MP:0005367 9.81 EGFR FGFR3 HRAS KRT7 PTEN PTGS2
13 pigmentation MP:0001186 9.65 CDKN2A EGFR ERBB3 PTEN TP53
14 respiratory system MP:0005388 9.61 CDKN2A EGFR ERBB2 ERBB3 FGFR3 HRAS
15 skeleton MP:0005390 9.28 BRINP1 CDKN2A EGFR ERBB2 FGFR3 HRAS
Sources

Drugs & Therapeutics for Transitional Cell Carcinoma

About this section

Drugs for Transitional Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 340)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vinblastine Approved Phase 2, Phase 3,Phase 3,Phase 1 865-21-4 241903 13342
2
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
3
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
4
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
5
Panitumumab Approved, Investigational Phase 3,Phase 2 339177-26-3 50070211
6
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
7
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
8
Amphotericin B Approved, Investigational Phase 2, Phase 3 1397-89-3 5280965 14956
9
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
10
Tocopherol Approved, Investigational Phase 3 1406-66-2 14986
11
Valrubicin Approved Phase 3,Phase 2,Phase 1 56124-62-0 41744
12
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
13
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
14
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
15
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
16
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
17
Atezolizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1380723-44-3
18
Aminolevulinic acid Approved Phase 3 106-60-5 137
19
Nicotinamide Approved, Investigational Phase 3 98-92-0 936
20
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
21
Pembrolizumab Approved Phase 3,Phase 1,Phase 2,Early Phase 1 1374853-91-4
22
Pemetrexed Approved, Investigational Phase 3,Phase 2,Phase 1 150399-23-8, 137281-23-3 60843 446556
23
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
24
Hydroxocobalamin Approved Phase 3,Phase 2,Not Applicable 13422-51-0 15589840 11953898
25
Methylcobalamin Approved, Experimental, Investigational Phase 3,Phase 2 13422-55-4
26
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2 1177-87-3
27
Ramucirumab Approved, Investigational Phase 3,Phase 2,Phase 1 947687-13-0
28
Mannitol Approved, Investigational Phase 3,Phase 2 69-65-8 6251 453
29
Gefitinib Approved, Investigational Phase 3,Phase 2 184475-35-2 123631
30
Sargramostim Approved, Investigational Phase 2, Phase 3,Phase 1 123774-72-1, 83869-56-1
31
Lenvatinib Approved, Investigational Phase 3,Phase 1,Phase 2 417716-92-8
32
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
33
Durvalumab Approved, Investigational Phase 3,Phase 1,Phase 2 1428935-60-7
34
Olaparib Approved Phase 2, Phase 3,Phase 3,Phase 1 763113-22-0 23725625
35
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
36
Ethanol Approved Phase 3 64-17-5 702
37
Cephalexin Approved, Investigational, Vet_approved Phase 3 15686-71-2 27447
38
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
39
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
40
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
41
Ornithine Approved, Nutraceutical Phase 3 70-26-8, 3184-13-2 6262
42
Niacin Approved, Investigational, Nutraceutical Phase 3 59-67-6 938
43
Cyanocobalamin Approved, Nutraceutical Phase 3,Phase 2,Not Applicable 68-19-9 44176380
44
Glutamic Acid Approved, Nutraceutical Phase 3,Phase 1,Phase 2 56-86-0 33032
45
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
46
Lapatinib Approved March 2007, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 231277-92-2, 388082-78-8 208908 9941095
47 Tocotrienol Investigational Phase 3 6829-55-6
48
BCG vaccine Investigational Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
49
Fenretinide Investigational Phase 3 65646-68-6
50
Levulinic acid Experimental Phase 3 123-76-2 11579

Interventional clinical trials:

(show top 50) (show all 578)
# Name Status NCT ID Phase Drugs
1 Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU) Unknown status NCT01830231 Phase 2, Phase 3 Cabazitaxel;Vinflunine
2 I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations Unknown status NCT02818725 Phase 3 Chemotherapy;panitumumab
3 Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer Unknown status NCT00146276 Phase 3 gemcitabine
4 A Double Blind Randomised Study of Lapatinib and Placebo in Metastatic TCC of the Urothelium Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
5 Selenium and Vitamin E in Preventing Cancer Progression and Recurrence in Patients With Early-Stage Bladder Cancer Unknown status NCT00553345 Phase 3 selenium;vitamin E
6 Different Factors Affecting Patients With Newly Diagnosed Bladder Cancer Unknown status NCT00553124 Phase 3 selenium;vitamin E
7 Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Unknown status NCT00003725 Phase 3 valrubicin
8 Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
9 Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel Completed NCT01668459 Phase 2, Phase 3 Cabazitaxel
10 First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy Completed NCT00389155 Phase 2, Phase 3 Vinflunine;Gemcitabine
11 Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium Completed NCT00028756 Phase 3 doxorubicin hydrochloride;gemcitabine hydrochloride;vinblastine sulfate;methotrexate;cisplatin
12 Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract Completed NCT00315237 Phase 3 vinflunine and best supportive care
13 Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer. Completed NCT00330499 Phase 3 Cisplatin
14 Radiation Therapy or Surgery in Treating Patients Receiving Chemotherapy for Bladder Cancer Completed NCT00867347 Phase 3
15 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00003701 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine sulfate
16 Combination Chemotherapy in Treating Patients With Bladder Cancer Completed NCT00014534 Phase 3 cisplatin;doxorubicin hydrochloride;gemcitabine hydrochloride
17 Fenretinide in Treating Patients Who Have Undergone Surgery for Bladder Cancer Completed NCT00004154 Phase 3 Fenretinide
18 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine Completed NCT02101931 Phase 3 Amino levulinic Acid
19 High-Dose Multivitamins Compared to a Placebo in Preventing the Recurrence of Cancer in Patients With Early Stage Bladder Cancer Completed NCT00003623 Phase 3
20 Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer Completed NCT00406068 Phase 2, Phase 3 Mycobacterial cell wall-DNA complex
21 Radiation Therapy, Chemotherapy, or Observation in Treating Patients With Bladder Cancer Completed NCT00002490 Phase 3 mitomycin C
22 Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer Completed NCT00729287 Phase 3
23 Surgery and BCG in Treating Patients With Bladder Cancer Completed NCT00002990 Phase 3
24 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Completed NCT00445601 Phase 3 gemcitabine hydrochloride
25 Eflornithine in Treating Patients With Bladder Cancer Completed NCT00003814 Phase 3 eflornithine
26 Radiation Therapy With or Without Carbogen and Niacinamide in Treating Patients With Bladder Cancer Completed NCT00033436 Phase 3 carbogen
27 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
28 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer Completed NCT00022191 Phase 3 cisplatin;gemcitabine hydrochloride;paclitaxel
29 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
30 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium Completed NCT00003376 Phase 3 carboplatin;cisplatin;doxorubicin hydrochloride;methotrexate;paclitaxel;vinblastine
31 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium Completed NCT00014274 Phase 2, Phase 3 carboplatin;gemcitabine hydrochloride;methotrexate;vinblastine sulfate
32 Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma Recruiting NCT03296306 Phase 3 Treatment duration of cisplatin based chemotherapy
33 Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) Recruiting NCT03898180 Phase 3 Lenvatinib;Placebo for lenvatinib
34 Pemetrexed Maintenance in Patients With Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Recruiting NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
35 Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer Recruiting NCT03244384 Phase 3
36 An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer Recruiting NCT02632409 Phase 3
37 Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer Recruiting NCT03682068 Phase 3 Durvalumab;Tremelimumab;Cisplatin + Gemcitabine;Carboplatin + Gemcitabine
38 S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer Recruiting NCT03091660 Phase 3
39 Atezolizumab Trial in Endometrial Cancer - AtTEnd Recruiting NCT03603184 Phase 3 Atezolizumab;Placebos;Paclitaxel;Carboplatin
40 Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer Recruiting NCT01812369 Phase 3 GEMCITABINE CISPLATINE;METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF
41 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
42 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
43 Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer Recruiting NCT03775265 Phase 3 Atezolizumab;Cisplatin;Fluorouracil;Gemcitabine;Mitomycin
44 Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC Recruiting NCT02982395 Phase 3 Nanoxel®M;Mitomycin-C
45 Avelumab Program Rollover Study Recruiting NCT03815643 Phase 3 Avelumab
46 A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100) Recruiting NCT02603432 Phase 3
47 Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) Recruiting NCT03711032 Phase 3
48 Transurethral En Bloc Versus Standard Resection of Bladder Tumour Recruiting NCT02993211 Phase 3
49 Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma Active, not recruiting NCT03410693 Phase 2, Phase 3 Rogaratinib (BAY1163877);Chemotherapy
50 Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) Active, not recruiting NCT02853305 Phase 3 Cisplatin;Carboplatin;Gemcitabine

Search NIH Clinical Center for Transitional Cell Carcinoma

Cochrane evidence based reviews: carcinoma, transitional cell

Sources

Genetic Tests for Transitional Cell Carcinoma

About this section
Sources

Anatomical Context for Transitional Cell Carcinoma

About this section

MalaCards organs/tissues related to Transitional Cell Carcinoma:

42
Kidney, Lymph Node, Ovary, Testes, Colon, Brain, Cervix
Sources

Publications for Transitional Cell Carcinoma

About this section

Articles related to Transitional Cell Carcinoma:

(show top 50) (show all 3146)
# Title Authors Year
1
Cancer-Testis Antigens as New Candidate Diagnostic Biomarkers for Transitional Cell Carcinoma of Bladder. ( 29058301 )
2019
2
Novel use of air in laser ablation of bladder transitional cell carcinoma. ( 30286637 )
2019
3
Proteinaceous Renal Stones in a Kidney Transplant Candidate Presenting as Bilateral Filling Defects Suspicious for Upper Urinary Tract Transitional Cell Carcinoma. ( 30359706 )
2019
4
Primary transitional cell carcinoma of penis - A rare presentation. ( 30505693 )
2019
5
Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA: a SEER-based analysis. ( 30630456 )
2019
6
Comparison of different prognostic models for predicting cancer-specific survival in bladder transitional cell carcinoma. ( 30657341 )
2019
7
Differential expression of S1P receptor subtypes in human bladder transitional cell carcinoma. ( 30712233 )
2019
8
Clinically diagnosed primary transitional cell carcinoma of the colon: A case report. ( 30739874 )
2019
9
Application of fluorescence in situ hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese population. ( 30775255 )
2019
10
The impact of narrow band imaging (NBI) in the detection and resection of bladder tumour in transitional cell carcinoma of the bladder: A prospective, blinded, sequential intervention randomized controlled trial. ( 30822478 )
2019
11
Strongyloides stercoralis larvae in the urine of a patient with transitional cell carcinoma of the bladder: a case report. ( 30956458 )
2019
12
Glutathione S-transferase theta genotypes and environmental exposures in the risk of canine transitional cell carcinoma. ( 31008543 )
2019
13
Survival analysis in dogs with urinary transitional cell carcinoma that underwent whole-body computed tomography at diagnosis. ( 31012230 )
2019
14
A rare case of coexisting lacrimal sac adenocarcinoma and transitional cell carcinoma. ( 30481853 )
2018
15
Enterovesical Fistula Secondary to Transitional Cell Carcinoma of the Bladder. ( 30474067 )
2018
16
A patient with acquired factor X deficiency and metastatic transitional cell carcinoma of the bladder: is there a link between metastasis and factor deficiency in solid tumors? ( 29130135 )
2018
17
Transitional Cell Carcinoma of Lacrimal Sac. ( 28582372 )
2018
18
ODF4, MAGEA3, and MAGEB4: Potential Biomarkers in Patients with Transitional Cell Carcinoma ( 28865418 )
2018
19
Overexpression of HER-2 via immunohistochemistry in canine urinary bladder transitional cell carcinoma - A marker of malignancy and possible therapeutic target. ( 28871659 )
2018
20
Expression of receptor tyrosine kinase targets PDGFR-β, VEGFR2 and KIT in canine transitional cell carcinoma. ( 28884928 )
2018
21
Iodine Content Analysis Using Dual-Energy Computed Tomography as a Biomarker of Transitional Cell Carcinoma, an Experience with Separation of the Clotted Blood and Tumorous Tissue. ( 29277821 )
2018
22
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy. ( 29416444 )
2018
23
In vitro evaluation of a simulated pneumoperitoneum environment using carbon dioxide on canine transitional cell carcinoma. ( 29484672 )
2018
24
Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium. ( 29492236 )
2018
25
Quantitative evaluation of canine urinary bladder transitional cell carcinoma using contrast-enhanced ultrasonography. ( 29530040 )
2018
26
Screening for canine transitional cell carcinoma (TCC) by SERS-based quantitative urine cytology. ( 29597048 )
2018
27
Cytological Findings of a Rare Case of Transitional Cell Carcinoma Bladder Presenting with Supraclavicular Lymphnode Metastasis. ( 29643666 )
2018
28
Coincidental Bladder Cuff Transitional Cell Carcinoma in Nephroureterectomy Specimens: Risk Factors, Prognosis and Clinical Implementation. ( 29687437 )
2018
29
Prognostic Value of Soluble Death Receptor Ligands in Patients with Transitional Cell Carcinoma of Bladder. ( 29719304 )
2018
30
LncRNA MALAT1 promotes tumor growth and metastasis by targeting miR-124/foxq1 in bladder transitional cell carcinoma (BTCC). ( 29736319 )
2018
31
Synchronous ipsilateral renal cell carcinoma and transitional cell carcinoma of the renal pelvic with complete remission of TCC after neoadjuvant chemotherapy. ( 29888183 )
2018
32
Canine urinary bladder transitional cell carcinoma tumor volume is dependent on imaging modality and measurement technique. ( 29989254 )
2018
33
Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles. ( 30059451 )
2018
34
Atezolizumab-associated vitiligo-like leukoderma in a patient with transitional cell carcinoma. ( 30091457 )
2018
35
Presurgical diagnostic difficulties in an asymptomatic patient with primary transitional cell carcinoma of the oviduct: case report. ( 30150917 )
2018
36
Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma. ( 30177237 )
2018
37
Anti-tumour effect of lapatinib in canine transitional cell carcinoma cell lines. ( 30246405 )
2018
38
Metastasis to gluteal muscle from high grade transitional cell carcinoma of bladder. Report of a case and review of literature. ( 30259916 )
2018
39
Silibinin attenuates TGF‑β1‑induced migration and invasion via EMT suppression and is associated with COX‑2 downregulation in bladder transitional cell carcinoma. ( 30272315 )
2018
40
BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). ( 30279015 )
2018
41
Transitional cell carcinoma of endometrium: a case report of rare pure form. ( 30479627 )
2018
42
SPAG9 regulates HEF1 expression and drives EMT in bladder transitional cell carcinoma via rac1 signaling pathway. ( 30662804 )
2018
43
Posterior reversible encephalopathy syndrome mimicking brain metastases in a patient with metastatic transitional cell carcinoma. ( 27726296 )
2017
44
High-grade transitional cell carcinoma masquerading as a xanthogranulomatous pyelonephritis and perinephric abscess. ( 28491170 )
2017
45
Non-transitional cell carcinoma of the upper urinary tract: A case series among 305 cases at a tertiary urology institute. ( 28216943 )
2017
46
Clinical outcome of partial cystectomy for transitional cell carcinoma of the canine bladder. ( 28217972 )
2017
47
Wild-type p53-induced phosphatase 1 is a prognostic marker and therapeutic target in bladder transitional cell carcinoma. ( 28356972 )
2017
48
Impact of BCL2 polymorphisms on survival in transitional cell carcinoma of the bladder. ( 28417194 )
2017
49
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). ( 28419193 )
2017
50
Stage IIIC transitional cell carcinoma and serous carcinoma of the ovary have similar outcomes when treated with platinum-based chemotherapy. ( 28506948 )
2017
Sources

Variations for Transitional Cell Carcinoma

About this section

Copy number variations for Transitional Cell Carcinoma from CNVD:

7 (show top 50) (show all 92)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 26136 1 197500000 205300000 Amplification LRRN2 Urothelial cell carcinoma
2 26141 1 197500000 205300000 Amplification MDM4 Urothelial cell carcinoma
3 26154 1 197500000 205300000 Loss Urothelial cell carcinoma
4 42679 10 3800000 6700000 Amplification PFKFB3 Urothelial cell carcinoma
5 49670 11 110000000 115400000 Loss ANKK1 Urothelial cell carcinoma
6 49671 11 110000000 115400000 Loss DRD2 Urothelial cell carcinoma
7 49672 11 110000000 115400000 Loss NCAM1 Urothelial cell carcinoma
8 49673 11 110000000 115400000 Loss TTC12 Urothelial cell carcinoma
9 52333 11 16100000 21600000 Loss PLEKHA7 Urothelial cell carcinoma
10 58688 11 69200000 70700000 Amplification CCND1 Urothelial cell carcinoma
11 58689 11 69200000 70700000 Amplification FGF19 Urothelial cell carcinoma
12 58690 11 69200000 70700000 Amplification FGF3 Urothelial cell carcinoma
13 58692 11 69200000 70700000 Amplification FGF4 Urothelial cell carcinoma
14 58694 11 69200000 70700000 Amplification ORAOV1 Urothelial cell carcinoma
15 58695 11 69200000 70700000 Amplification TPCN2 Urothelial cell carcinoma
16 58889 11 70700000 74900000 Amplification Urothelial cell carcinoma
17 58890 11 70700000 74900000 Amplification C11orf76 Urothelial cell carcinoma
18 58891 11 70700000 74900000 Amplification SHANK2 Urothelial cell carcinoma
19 64483 12 128700000 132349534 Loss FZD10 Urothelial cell carcinoma
20 69470 12 55200000 56300000 Amplification ARHGAP9 Urothelial cell carcinoma
21 69471 12 55200000 56300000 Amplification DCTN2 Urothelial cell carcinoma
22 69472 12 55200000 56300000 Amplification GLI1 Urothelial cell carcinoma
23 69473 12 55200000 56300000 Amplification INHBC Urothelial cell carcinoma
24 69474 12 55200000 56300000 Amplification KIF5A Urothelial cell carcinoma
25 69475 12 55200000 61400000 Amplification CDK4 Urothelial cell carcinoma
26 69476 12 55200000 61400000 Amplification METTL1 Urothelial cell carcinoma
27 69477 12 55200000 61400000 Amplification TSFM Urothelial cell carcinoma
28 69795 12 56300000 61400000 Amplification FAM19A2 Urothelial cell carcinoma
29 69796 12 56300000 61400000 Amplification SLC16A7 Urothelial cell carcinoma
30 70900 12 66000000 69800000 Amplification CNOT2 Urothelial cell carcinoma
31 70901 12 66000000 69800000 Amplification CPM Urothelial cell carcinoma
32 70902 12 66000000 69800000 Amplification IFNG Urothelial cell carcinoma
33 70903 12 66000000 69800000 Amplification IL22 Urothelial cell carcinoma
34 70904 12 66000000 69800000 Amplification IL26 Urothelial cell carcinoma
35 70910 12 66000000 69800000 Amplification MDM2 Urothelial cell carcinoma
36 70911 12 66000000 69800000 Amplification TM4SF3 Urothelial cell carcinoma
37 71411 12 69800000 74100000 Amplification LGR5 Urothelial cell carcinoma
38 71412 12 69800000 74100000 Amplification THAP2 Urothelial cell carcinoma
39 71413 12 69800000 74100000 Amplification TMEM19 Urothelial cell carcinoma
40 71414 12 69800000 74100000 Amplification TPH2 Urothelial cell carcinoma
41 71668 12 74100000 78700000 Amplification NAV3 Urothelial cell carcinoma
42 72907 12 87500000 91200000 Amplification KITLG Urothelial cell carcinoma
43 73109 12 91200000 94800000 Amplification PLXNC1 Urothelial cell carcinoma
44 79797 13 77800000 86500000 Loss Urothelial cell carcinoma
45 94764 15 70400000 73100000 Loss SDFR1 Urothelial cell carcinoma
46 109762 17 28800000 35600000 Amplification ERBB2 Urothelial cell carcinoma
47 109763 17 28800000 35600000 Amplification TCAP Urothelial cell carcinoma
48 123109 18 66900000 71300000 Loss Urothelial cell carcinoma
49 123110 18 66900000 71300000 Loss SDCCAG33 Urothelial cell carcinoma
50 123111 18 66900000 71300000 Loss ZADH2 Urothelial cell carcinoma
Sources

Expression for Transitional Cell Carcinoma

About this section
Search GEO for disease gene expression data for Transitional Cell Carcinoma.
Sources

Pathways for Transitional Cell Carcinoma

About this section

Pathways related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 65
Show member pathways
 13.87 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
2
TGF-Beta Pathway 65
Show member pathways
 13.56 CDH1 EGFR ERBB2 ERBB3 FGFR3 HRAS
3
Developmental Biology 67
Show member pathways
 13.52 EGFR ERBB2 ERBB3 FGFR3 HRAS KRT18
4
Class I MHC mediated antigen processing and presentation 67
Show member pathways
 13.49 CDH1 EGFR ERBB2 ERBB3 FGFR3 HRAS
5
Cytokine Signaling in Immune system 67
Show member pathways
 13.37 EGFR ERBB2 ERBB3 FGFR3 HRAS IFNA2
6
Actin Nucleation by ARP-WASP Complex 65
Show member pathways
 13.02 CDH1 EGFR ERBB2 ERBB3 FGFR3 HRAS
7
Human cytomegalovirus infection 38
Show member pathways
 12.96 CDKN2A EGFR HRAS IFNA2 PTEN PTGS2
8
PI3K-Akt signaling pathway 38
Show member pathways
 12.95 EGFR ERBB2 ERBB3 FGFR3 HRAS IFNA2
9
NFAT and Cardiac Hypertrophy 65
Show member pathways
 12.89 EGFR ERBB2 ERBB3 FGFR3 HRAS PTEN
10
Endometrial cancer 38
Show member pathways
 12.87 CDH1 CDKN2A EGFR ERBB2 HRAS PTEN
11
Gastric cancer 38
Show member pathways
 12.77 CDH1 CDKN2A EGFR ERBB2 HRAS PTEN
12
MAPK signaling pathway 1 38
12.76 EGFR ERBB2 ERBB3 FGFR3 HRAS TP53
13
Downstream signaling events of B Cell Receptor (BCR) 67
Show member pathways
 12.71 EGFR ERBB2 ERBB3 FGFR3 HRAS PTEN
14
Development HGF signaling pathway 23
Show member pathways
 12.67 CDH1 ERBB2 ERBB3 HRAS PTEN PTGS2
15
ErbB signaling pathway 1 38
Show member pathways
 12.6 EGFR ERBB2 ERBB3 HRAS TP53
16
Pathways in cancer 38
12.58 CDH1 CDKN2A EGFR ERBB2 FGFR3 HRAS
17
Glioma 38
Show member pathways
 12.57 CDH1 CDKN2A EGFR ERBB2 ERBB3 FGFR3
18
Development EGFR signaling pathway 23
Show member pathways
 12.55 CDH1 EGFR ERBB2 ERBB3 HRAS TP53
19
mTOR signaling pathway (KEGG) 38
Show member pathways
 12.49 EGFR ERBB2 ERBB3 FGFR3 HRAS PTEN
20
Apoptosis Pathway 73
Show member pathways
 12.45 EGFR ERBB2 ERBB3 FGFR3 HRAS TP53
21
G-protein signaling RAC1 in cellular process 23
Show member pathways
 12.4 CDH1 EGFR ERBB2 ERBB3 FGFR3 HRAS
22
Signaling by ERBB2 67
Show member pathways
 12.33 EGFR ERBB2 ERBB3 HRAS
23
Development Ligand-independent activation of ESR1 and ESR2 23
Show member pathways
 12.33 EGFR ERBB2 ERBB3 HRAS PTGS2
24
Proteoglycans in cancer 38
12.31 EGFR ERBB2 ERBB3 HRAS TP53
25
VEGF Signaling Pathway 68 62
Show member pathways
 12.26 EGFR FGFR3 HRAS PTEN
26
Colorectal Cancer Metastasis 65
12.22 CDH1 EGFR PTGS2 TP53
27
EGF/EGFR Signaling Pathway 1
12.21 EGFR ERBB2 HRAS PTEN
28
Cellular senescence (KEGG) 38
12.2 CDKN2A HRAS PTEN TP53
29
Integrated Breast Cancer Pathway 1
12.18 CDH1 EGFR PTEN TP53
30
Development EGFR signaling via small GTPases 23
Show member pathways
 12.16 EGFR ERBB2 HRAS PTEN
31
MAPK Signaling: Mitogen Stimulation Pathway 66
Show member pathways
 12.16 EGFR ERBB2 ERBB3 FGFR3 HRAS PTEN
32
Tyrosine Kinases / Adaptors 4
12.15 EGFR ERBB2 ERBB3 FGFR3
33
Transcription Androgen Receptor nuclear signaling 23
Show member pathways
 12.14 EGFR ERBB2 HRAS PTEN
34
AKT Signaling Pathway 68
12.1 EGFR ERBB2 ERBB3 FGFR3 HRAS PTEN
35
Signaling by PTK6 67
Show member pathways
 12.08 EGFR ERBB2 ERBB3 HRAS
36
MicroRNAs in cancer 38
12.08 CDKN2A EGFR ERBB2 ERBB3 FGFR3 HRAS
37
MAPK Pathway 73
Show member pathways
 12.05 EGFR ERBB2 ERBB3 TP53
38
DNA Damage Response (only ATM dependent) 1
11.99 CDKN2A ERBB2 HRAS PTEN TP53
39
Signaling by ERBB4 67
Show member pathways
 11.97 EGFR ERBB2 ERBB3 HRAS
40
Senescence and Autophagy in Cancer 1
11.96 CDKN2A HRAS PTEN TP53
41
Glioblastoma Multiforme 65
11.95 CDKN2A EGFR HRAS PTEN TP53
42
Small cell lung cancer 38
11.87 PTEN PTGS2 TP53
43
Platinum drug resistance 38
11.76 CDKN2A ERBB2 TP53
44
G-protein signaling_RhoA regulation pathway 23
11.76 EGFR ERBB2 ERBB3 FGFR3 HRAS
45
Adherens junction 38
11.75 CDH1 EGFR ERBB2
46
Pathways Affected in Adenoid Cystic Carcinoma 1
11.72 ERBB2 HRAS PTEN TP53
47
Agrin Interactions at Neuromuscular Junction 65
11.63 EGFR ERBB2 ERBB3 HRAS
48
Photodynamic therapy-induced AP-1 survival signaling. 1
11.58 CDKN2A EGFR TP53
49
Aryl Hydrocarbon Receptor 1
11.55 EGFR HRAS PTGS2
50
Central carbon metabolism in cancer 38
11.55 EGFR ERBB2 FGFR3 HRAS PTEN TP53
Sources

GO Terms for Transitional Cell Carcinoma

About this section

Cellular components related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.95 EGFR ERBB2 ERBB3 FGFR3 UPK1A UPK1B
2 endoplasmic reticulum GO:0005783 9.92 BRINP1 EGFR FGFR3 PTGS2 TP53 UBIAD1
3 receptor complex GO:0043235 9.67 EGFR ERBB2 ERBB3 FGFR3
4 basal plasma membrane GO:0009925 9.33 EGFR ERBB2 ERBB3
5 apical plasma membrane GO:0016324 9.23 EGFR ERBB2 ERBB3 PTEN UPK1A UPK1B
6 apical plasma membrane urothelial plaque GO:0120001 9.13 UPK1A UPK1B UPK3A
7 cytoplasm GO:0005737 10.1 BRINP1 CDH1 CDKN2A EGFR ERBB2 FGFR3

Biological processes related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.99 CDKN2A HRAS PTEN PTGS2 TP53
2 cell proliferation GO:0008283 9.95 EGFR ERBB2 HRAS PTEN TP53
3 apoptotic process GO:0006915 9.91 CDKN2A FGFR3 HRAS IFNA2 KRT20 PTEN
4 positive regulation of gene expression GO:0010628 9.88 CDKN2A ERBB2 ERBB3 HRAS PTEN TP53
5 peptidyl-tyrosine phosphorylation GO:0018108 9.86 EGFR ERBB2 ERBB3 FGFR3
6 positive regulation of protein kinase B signaling GO:0051897 9.84 EGFR ERBB2 ERBB3 FGFR3
7 MAPK cascade GO:0000165 9.83 EGFR ERBB2 ERBB3 FGFR3 HRAS
8 cell cycle arrest GO:0007050 9.81 BRINP1 CDKN2A HRAS TP53
9 response to organic substance GO:0010033 9.8 CDH1 PTEN PTGS2
10 Ras protein signal transduction GO:0007265 9.77 CDKN2A HRAS TP53
11 positive regulation of epithelial cell proliferation GO:0050679 9.76 EGFR ERBB2 HRAS
12 positive regulation of MAP kinase activity GO:0043406 9.75 EGFR ERBB2 HRAS
13 ERBB2 signaling pathway GO:0038128 9.65 EGFR ERBB2 ERBB3
14 regulation of cell motility GO:2000145 9.63 EGFR ERBB2 ERBB3
15 cell surface receptor signaling pathway GO:0007166 9.63 EGFR ERBB2 HRAS IFNA2 UPK1A UPK1B
16 maternal behavior GO:0042711 9.62 BRINP1 PTEN
17 epithelial cell differentiation GO:0030855 9.62 UPK1A UPK1B UPK2 UPK3A
18 replicative senescence GO:0090399 9.61 CDKN2A TP53
19 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.61 EGFR TP53
20 negative regulation of ERBB signaling pathway GO:1901185 9.57 EGFR ERBB2
21 negative regulation of immature T cell proliferation in thymus GO:0033088 9.52 CDKN2A ERBB2
22 positive regulation of MAPK cascade GO:0043410 9.43 ERBB2 FGFR3 HRAS
23 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.26 EGFR FGFR3 HRAS PTEN
24 negative regulation of signal transduction GO:0009968 9.19 ERBB3
25 negative regulation of apoptotic process GO:0043066 9.02 EGFR KRT18 PTEN PTGS2 TP53

Molecular functions related to Transitional Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 CDH1 EGFR ERBB2 ERBB3 FGFR3 PTEN
2 nucleotide binding GO:0000166 9.72 EGFR ERBB2 ERBB3 FGFR3 HRAS
3 protein binding GO:0005515 9.6 BRINP1 CDH1 CDKN2A EGFR ERBB2 ERBB3
4 protein phosphatase binding GO:0019903 9.58 EGFR ERBB2 TP53
5 transmembrane signaling receptor activity GO:0004888 9.54 EGFR ERBB2 ERBB3
6 protein tyrosine kinase activity GO:0004713 9.46 EGFR ERBB2 ERBB3 FGFR3
7 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.26 EGFR ERBB2 ERBB3 FGFR3
Sources

Sources for Transitional Cell Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....